During the 2018 Annual Meeting of the Connective Tissue Oncology Society, Jason Roszik, PhD, MBA, of the MD Anderson Cancer Center, discusses the use of next-generation sequencing in intimal sarcoma.<br />
Jason Roszik, PhD, MBA, of the MD Anderson Cancer Center, discusses his review of the available molecular and sequencing data, and his findings that patients with intimal sarcoma, a rare type of sarcoma, have alterations that may hold clinical relevance.
Patients with intimal sarcoma may have alterations of the MDM2, CDK, and PDGFR pathways. However, these patients are typically excluded from or do not participate in clinical trials, making it difficult to determine which patients would benefit the most from genomically-matched therapies.
The identified targets may be actionable with drugs that are already approved to treat sarcoma, but patients with intimal sarcoma will need to be included in clinical trials to better understand whether these treatments are options for this patient population. Furthermore, additional molecular and genomic testing will be necessary to identify these potentially targetable alterations.